Jnc7 PowerPoint PPT Presentations

All Time
Show:
Recommended
Sort by:
Hypertension Beyond JNC7 PowerPoint PPT Presentation
Hypertension Beyond JNC7 - Age (men 55, women 65) Family History of premature CVD (men 55 or women 65) ... Kaplan-Meier curves for all-cause and cardiovascular deaths with no blood ...
Age (men 55, women 65) Family History of premature CVD (men 55 or women 65) ... Kaplan-Meier curves for all-cause and cardiovascular deaths with no blood ...
| PowerPoint PPT presentation | free to view
Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL PowerPoint PPT Presentation
Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL - Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL
Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL
| PowerPoint PPT presentation | free to view
Improving Blood Pressure Treatment in the Community: How the JNC7 Recommendations and ALLHAT Results PowerPoint PPT Presentation
Improving Blood Pressure Treatment in the Community: How the JNC7 Recommendations and ALLHAT Results - DBP significantly lower in the amlodipine group (~1 mm Hg), similar in the lisinopril group. ... 1/ 1,-2/ 0 amlodipine (HF only), lisinopril ...
DBP significantly lower in the amlodipine group (~1 mm Hg), similar in the lisinopril group. ... 1/ 1,-2/ 0 amlodipine (HF only), lisinopril ...
| PowerPoint PPT presentation | free to view
Improving Blood Pressure Treatment in the Community: How the JNC7 Recommendations and ALLHAT Results PowerPoint PPT Presentation
Improving Blood Pressure Treatment in the Community: How the JNC7 Recommendations and ALLHAT Results - Impact of New Results, Guidelines, & Traditional Approaches to Dissemination ... Initial drug therapy for most should be either thiazide-type diuretic alone or ...
Impact of New Results, Guidelines, & Traditional Approaches to Dissemination ... Initial drug therapy for most should be either thiazide-type diuretic alone or ...
| PowerPoint PPT presentation | free to view
Assessment and Management of Patients with Hypertension PowerPoint PPT Presentation
Assessment and Management of Patients with Hypertension - JNC7 definition: ... At which classification stage should lifestyle modifications begin? Review: ... Identify factors involved in the control of blood pressure. ...
JNC7 definition: ... At which classification stage should lifestyle modifications begin? Review: ... Identify factors involved in the control of blood pressure. ...
| PowerPoint PPT presentation | free to view
Adherencia al Tratamiento de la Hipertensi PowerPoint PPT Presentation
Adherencia al Tratamiento de la Hipertensi - Title: II Curso Multidisciplinario de Salud Author: RUBEN OMAR YZA VILLANUEVA Last modified by: William Moguel Created Date: 3/30/2004 8:33:14 PM Document ...
Title: II Curso Multidisciplinario de Salud Author: RUBEN OMAR YZA VILLANUEVA Last modified by: William Moguel Created Date: 3/30/2004 8:33:14 PM Document ...
| PowerPoint PPT presentation | free to view
INDIVIDUALISED THERAPY FOR HYPERTENSION PowerPoint PPT Presentation
INDIVIDUALISED THERAPY FOR HYPERTENSION - Hypertension Introduction to Primary Care: a course of the Center of Post Graduate Studies in FM ... In individuals considered salt-sensitive, such as: ...
Hypertension Introduction to Primary Care: a course of the Center of Post Graduate Studies in FM ... In individuals considered salt-sensitive, such as: ...
| PowerPoint PPT presentation | free to download
Drugs acting on cardiovascular system(CVS) PowerPoint PPT Presentation
Drugs acting on cardiovascular system(CVS) - Chapter 6. Drugs acting on cardiovascular system(CVS)
Chapter 6. Drugs acting on cardiovascular system(CVS)
| PowerPoint PPT presentation | free to view
Resistant Hypertension PowerPoint PPT Presentation
Resistant Hypertension - Resistant Hypertension Prof. Dr. Sarma VSN Rachakonda M.D (Internal Medicine)., M.Sc., (Canada), FCGP, FICP, FIMSA, FRCP (G), FCCP (USA), FACP (USA)
Resistant Hypertension Prof. Dr. Sarma VSN Rachakonda M.D (Internal Medicine)., M.Sc., (Canada), FCGP, FICP, FIMSA, FRCP (G), FCCP (USA), FACP (USA)
| PowerPoint PPT presentation | free to download
Nincs diac PowerPoint PPT Presentation
Nincs diac - Title: Nincs diac m Author: Hintalan Last modified by: Hantos M nika Created Date: 8/6/2005 5:57:35 PM Document presentation format: Diavet t s a k perny re
Title: Nincs diac m Author: Hintalan Last modified by: Hantos M nika Created Date: 8/6/2005 5:57:35 PM Document presentation format: Diavet t s a k perny re
| PowerPoint PPT presentation | free to view
Malignant Hypertension: Management Without Headaches PowerPoint PPT Presentation
Malignant Hypertension: Management Without Headaches - Two-drug combination for most(usually thiazide-type diuretic and ACEI or ARB or BB or CCB) ... Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, ...
Two-drug combination for most(usually thiazide-type diuretic and ACEI or ARB or BB or CCB) ... Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, ...
| PowerPoint PPT presentation | free to view
Management of Hypertension: An Overview PowerPoint PPT Presentation
Management of Hypertension: An Overview - Management of Hypertension: An Overview & Update 11/12/11 Marcus Weiser, DO PGY3 Chief Resident Via Christi Family Medicine Outline Classification Causes History, PE ...
Management of Hypertension: An Overview & Update 11/12/11 Marcus Weiser, DO PGY3 Chief Resident Via Christi Family Medicine Outline Classification Causes History, PE ...
| PowerPoint PPT presentation | free to view
The Rationale for Initiating Therapy with FixedDose Combinations in Hypertension PowerPoint PPT Presentation
The Rationale for Initiating Therapy with FixedDose Combinations in Hypertension - New Orleans, LA. Disclosure: Grant support: Astra Zeneca, Amgen, Abbott, Novartis, The National Institutes of ... Consultant for Novartis, Pfizer, Boehringer ...
New Orleans, LA. Disclosure: Grant support: Astra Zeneca, Amgen, Abbott, Novartis, The National Institutes of ... Consultant for Novartis, Pfizer, Boehringer ...
| PowerPoint PPT presentation | free to download
EPIDEMIOLOGY OF HYPERTENSION (HT) PowerPoint PPT Presentation
EPIDEMIOLOGY OF HYPERTENSION (HT) - ... S.creatinin level 2 mg/dl RF Vessels: Dissecting aneurysm Symptomatic occlusive disease Classification of HT by Causes I.Primary ...
... S.creatinin level 2 mg/dl RF Vessels: Dissecting aneurysm Symptomatic occlusive disease Classification of HT by Causes I.Primary ...
| PowerPoint PPT presentation | free to view
HYPERTENSION ABC PowerPoint PPT Presentation
HYPERTENSION ABC - HYPERTENSION ABC & Update Mahmoud Khattab, Ph.D. Professor of Pharmacology & Toxicology * Recall (Self-Assessment) Questions Define different stages of HTN according ...
HYPERTENSION ABC & Update Mahmoud Khattab, Ph.D. Professor of Pharmacology & Toxicology * Recall (Self-Assessment) Questions Define different stages of HTN according ...
| PowerPoint PPT presentation | free to view
Clinical Guidelines PowerPoint PPT Presentation
Clinical Guidelines - Uruz - Gradual conversion of free-text clinical guidelines into a machine ... Not try to create a data model that replicates everything that an EMR holds, but ...
Uruz - Gradual conversion of free-text clinical guidelines into a machine ... Not try to create a data model that replicates everything that an EMR holds, but ...
| PowerPoint PPT presentation | free to view
ALLHAT Antihypertensive Trial Results by Baseline Diabetic PowerPoint PPT Presentation
ALLHAT Antihypertensive Trial Results by Baseline Diabetic - ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status ... Diabetes Incidence (follow-up fasting glucose 126 mg/dL) ...
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status ... Diabetes Incidence (follow-up fasting glucose 126 mg/dL) ...
| PowerPoint PPT presentation | free to view
Making your office a diabetes center of excellence PowerPoint PPT Presentation
Making your office a diabetes center of excellence - Discuss the 4 year experience of the DMCP with using a diabetes registry and ... Reduction of LDL (lousy cholesterol) less than 100 or 70, and systolic blood ...
Discuss the 4 year experience of the DMCP with using a diabetes registry and ... Reduction of LDL (lousy cholesterol) less than 100 or 70, and systolic blood ...
| PowerPoint PPT presentation | free to view
The Rationale for Initiating Therapy with Fixed-Dose Combinations in Hypertension PowerPoint PPT Presentation
The Rationale for Initiating Therapy with Fixed-Dose Combinations in Hypertension - The Rationale for Initiating Therapy with Fixed-Dose Combinations in Hypertension Thomas D. Giles, M.D. Tulane University School of Medicine New Orleans, LA
The Rationale for Initiating Therapy with Fixed-Dose Combinations in Hypertension Thomas D. Giles, M.D. Tulane University School of Medicine New Orleans, LA
| PowerPoint PPT presentation | free to view
Chronic Kidney Disease (CKD) in the Hospitalized Patient PowerPoint PPT Presentation
Chronic Kidney Disease (CKD) in the Hospitalized Patient - Chronic Kidney Disease (CKD) in the ... Syncope in Renal Disease CVD and CKD Dyslipidemia CV Mortality CVD in patients with or without CKD, ...
Chronic Kidney Disease (CKD) in the ... Syncope in Renal Disease CVD and CKD Dyslipidemia CV Mortality CVD in patients with or without CKD, ...
| PowerPoint PPT presentation | free to view
Hypertension Chapter 15 PowerPoint PPT Presentation
Hypertension Chapter 15 - ALLHAT confirms 1st line role of thiazide diuretics ... Regular aerobic physical activity (at least 30 min/day, most days of the week) 4 9 ...
ALLHAT confirms 1st line role of thiazide diuretics ... Regular aerobic physical activity (at least 30 min/day, most days of the week) 4 9 ...
| PowerPoint PPT presentation | free to view
* 5 yr risk of CV event with hyperlipidemia: ALERT study 12 PowerPoint PPT Presentation
* 5 yr risk of CV event with hyperlipidemia: ALERT study 12 - * 5 yr risk of CV event with hyperlipidemia: ALERT study 12% (cf USRDS 11% at 3 yrs) 5 yr risk of CV event with hyperlipidemia: ALERT study 12% (cf USRDS 11% at 3 yrs ...
* 5 yr risk of CV event with hyperlipidemia: ALERT study 12% (cf USRDS 11% at 3 yrs) 5 yr risk of CV event with hyperlipidemia: ALERT study 12% (cf USRDS 11% at 3 yrs ...
| PowerPoint PPT presentation | free to view
Immunosuppressants and Hypertension PowerPoint PPT Presentation
Immunosuppressants and Hypertension - Adverse Effects of MMF & MPA. Gastritis, anorexia, cramping, diarrhea ... Practical Tips for MMF & MPA. Take with food. Do not crush, cut or chew tablets (MPA) ...
Adverse Effects of MMF & MPA. Gastritis, anorexia, cramping, diarrhea ... Practical Tips for MMF & MPA. Take with food. Do not crush, cut or chew tablets (MPA) ...
| PowerPoint PPT presentation | free to view
URGENCES HYPERTENSIVES PowerPoint PPT Presentation
URGENCES HYPERTENSIVES - ... paroxysme tensionnel sur HTA franche avec hyperaldost ronisme possible Hospitalisation en cardiologie conven-tionnelle : bilan d'HTA, ...
... paroxysme tensionnel sur HTA franche avec hyperaldost ronisme possible Hospitalisation en cardiologie conven-tionnelle : bilan d'HTA, ...
| PowerPoint PPT presentation | free to download
The Diabetes Registry: A Cost-Effective Approach to Practicing Quality Medicine PowerPoint PPT Presentation
The Diabetes Registry: A Cost-Effective Approach to Practicing Quality Medicine - The Diabetes Registry: A Cost-Effective Approach to Practicing Quality Medicine Edward Shahady, MD Medical Director, Diabetes Clinician Program Florida Academy of ...
The Diabetes Registry: A Cost-Effective Approach to Practicing Quality Medicine Edward Shahady, MD Medical Director, Diabetes Clinician Program Florida Academy of ...
| PowerPoint PPT presentation | free to view
Towards an Evidence Based Treatment Strategy in Hypertension PowerPoint PPT Presentation
Towards an Evidence Based Treatment Strategy in Hypertension - Towards an Evidence Based Treatment Strategy in Hypertension Tony Woolley M.D. Park Nicollet Clinic Clinical Associate Professor of Medicine, University of Minnesota
Towards an Evidence Based Treatment Strategy in Hypertension Tony Woolley M.D. Park Nicollet Clinic Clinical Associate Professor of Medicine, University of Minnesota
| PowerPoint PPT presentation | free to view
Increased Blood Pressure in the Emergency Department: Pain, Anxiety, or Undiagnosed Hypertension AHR PowerPoint PPT Presentation
Increased Blood Pressure in the Emergency Department: Pain, Anxiety, or Undiagnosed Hypertension AHR - Sustained blood pressure elevation. Highest and lowest SBP and DBP deleted ... Classified as sustained elevation if SBP 140 or DBP 90 mm Hg. Pain and Anxiety ...
Sustained blood pressure elevation. Highest and lowest SBP and DBP deleted ... Classified as sustained elevation if SBP 140 or DBP 90 mm Hg. Pain and Anxiety ...
| PowerPoint PPT presentation | free to view
7th Annual International Diovan Symposium PowerPoint PPT Presentation
7th Annual International Diovan Symposium - Title: Val-HeFT: Independent Predictors of AF Occurrence Author: Jeff Gold Last modified by: dubinta1 Created Date: 5/19/2005 10:21:57 AM Document presentation format
Title: Val-HeFT: Independent Predictors of AF Occurrence Author: Jeff Gold Last modified by: dubinta1 Created Date: 5/19/2005 10:21:57 AM Document presentation format
| PowerPoint PPT presentation | free to download
MANAGEMENT OF HYPERTENSION IN WOMEN AND PREGNANCY PowerPoint PPT Presentation
MANAGEMENT OF HYPERTENSION IN WOMEN AND PREGNANCY - Professor of Medicine, and Physiology & Biophysics ... Initial sonogram at 18 to 20 weeks gestation. Fetal growth carefully assessed thereafter. ...
Professor of Medicine, and Physiology & Biophysics ... Initial sonogram at 18 to 20 weeks gestation. Fetal growth carefully assessed thereafter. ...
| PowerPoint PPT presentation | free to view
ESH/ESC Guidelines: PowerPoint PPT Presentation
ESH/ESC Guidelines: - Definitions and Classification of BP Levels (mmHg) Category Optimal Normal High normal Grade 1 hypertension (mild) Grade 2 hypertension (moderate) Grade 3 ...
Definitions and Classification of BP Levels (mmHg) Category Optimal Normal High normal Grade 1 hypertension (mild) Grade 2 hypertension (moderate) Grade 3 ...
| PowerPoint PPT presentation | free to view
Makrovaskularna bolest PowerPoint PPT Presentation
Makrovaskularna bolest - this is a test comment ... Section 5 | 2 of 4 Curriculum Module III-7d | Cardiovascular disease Makrovaskularna bolest Koronarna bolest Cerebrovaskularna bolest ...
this is a test comment ... Section 5 | 2 of 4 Curriculum Module III-7d | Cardiovascular disease Makrovaskularna bolest Koronarna bolest Cerebrovaskularna bolest ...
| PowerPoint PPT presentation | free to view
Women in Academic Medicine: Agents of Transformational Change PowerPoint PPT Presentation
Women in Academic Medicine: Agents of Transformational Change - Language and Women s Academic Advancement Molly Carnes, MD, MS Professor, Depts of Medicine, Psychiatry, and Industrial & Systems Engineering
Language and Women s Academic Advancement Molly Carnes, MD, MS Professor, Depts of Medicine, Psychiatry, and Industrial & Systems Engineering
| PowerPoint PPT presentation | free to view
Weiping Zhang, MD. PhD. Associate professor Dept. Pharmacology, Medical School, Zhejiang University weiping601@zju.edu.cn PowerPoint PPT Presentation
Weiping Zhang, MD. PhD. Associate professor Dept. Pharmacology, Medical School, Zhejiang University weiping601@zju.edu.cn - Pharmacology for cardiovascular system Part 3 Antihypertensive Drugs Weiping Zhang, MD. PhD. Associate professor Dept. Pharmacology, Medical School, Zhejiang University
Pharmacology for cardiovascular system Part 3 Antihypertensive Drugs Weiping Zhang, MD. PhD. Associate professor Dept. Pharmacology, Medical School, Zhejiang University
| PowerPoint PPT presentation | free to view
Cardiovascular Diseases PowerPoint PPT Presentation
Cardiovascular Diseases - Thickening and hardening of ... Fatty streaks develop along the intima (innermost layer ... macrophages and increasing intravascular tone and coagulability ...
Thickening and hardening of ... Fatty streaks develop along the intima (innermost layer ... macrophages and increasing intravascular tone and coagulability ...
| PowerPoint PPT presentation | free to view
1. dia PowerPoint PPT Presentation
1. dia - The Seventh Report of the Joint National Committee on ... Albuminuria 0.0001. 2.74. CVD. P value. Odds Ratio. Variable. A diabeteses neuropathia oki kezel se ...
The Seventh Report of the Joint National Committee on ... Albuminuria 0.0001. 2.74. CVD. P value. Odds Ratio. Variable. A diabeteses neuropathia oki kezel se ...
| PowerPoint PPT presentation | free to download
AHAACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vasc PowerPoint PPT Presentation
AHAACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vasc - AHA/ACC guidelines for secondary prevention for patients with coronary and other ... 2.0 - 3.0 for paroxysmal or chronic atrial fibrillation or flutter, and in post ...
AHA/ACC guidelines for secondary prevention for patients with coronary and other ... 2.0 - 3.0 for paroxysmal or chronic atrial fibrillation or flutter, and in post ...
| PowerPoint PPT presentation | free to view


Home About Us Terms and Conditions Privacy Policy Contact Us
Copyright 2024 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
jnc7 — Search results on PowerShow.com